There have been a spate of recent Op-Eds and items related to the decision the FDA has to approve, or not, this Alzheimer anti-amyloid monoclonal antibody therapy.

An advocacy group, Us Against Alzheimers, has been pushing for approval, Feb 23, saying the med may provide more time to patients.

NYT Op-Ed May 28 by two dementia academic doctors:  “People Want An Alzheimer’s Drug.  This Isn’t The One”  [might be behind a paywall]

From a biotech industry newsletter, June 4:

Whatever the FDA decides on aducanumab, Alzheimer’s research is finally, mostly, kind of moving beyond the amyloid hypothesis

From STATnews, June 4:

A landmark Alzheimer’s drug approval would likely deepen racial inequities in dementia care

And

Aducanumab for AD…..what if? Thought experiment by Dr. J. Karlawish